B型肝炎治療薬の世界市場2018-2022

◆英語タイトル:Global Hepatitis B Therapeutics Market 2018-2022
◆商品コード:IRTNTR23586
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月4日
◆ページ数:110
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、B型肝炎治療薬の世界市場について調査・分析し、市場概要、市場環境、B型肝炎治療薬市場規模、用途別(薬剤、ワクチン)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・B型肝炎治療薬の世界市場概要
・B型肝炎治療薬の世界市場環境
・B型肝炎治療薬の世界市場動向
・B型肝炎治療薬の世界市場規模
・B型肝炎治療薬の世界市場:業界構造分析
・B型肝炎治療薬の世界市場:用途別(薬剤、ワクチン)
・B型肝炎治療薬の世界市場:地域別市場規模・分析
・B型肝炎治療薬の北米市場規模・予測
・B型肝炎治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・B型肝炎治療薬のアジア太平洋市場規模・予測
・B型肝炎治療薬の主要国分析
・B型肝炎治療薬の世界市場:意思決定フレームワーク
・B型肝炎治療薬の世界市場:成長要因、課題
・B型肝炎治療薬の世界市場:競争環境
・B型肝炎治療薬の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Bristol-Myers Squibb、F. Hoffmann-La Roche、Gilead、GlaxoSmithKline、and Merck Sharp & Dohmeなどです。
【レポートの概要】

About this market
Global hepatitis B therapeutics market is fragmented market, as many pharmaceutical companies are developing drugs for the treatments of hepatitis B. Also, several companies are forming collaborations to increase their research toward the hepatitis B drug development. These types of strategic collaboration between the pharmaceutical companies will propel the hepatitis B therapeutics development and lead to increase the growth of the market during our forecast period. This will boost the growth of the hepatitis B therapeutics market at a CAGR of over 2% during the forecast period.
Market Overview
Increasing prevalence of hepatitis B in infants
The increase in the prevalence of hepatitis B in infants, the companies are developing various and drugs against hepatitis B virus. This leads to an increase in the global market during the forecast period.
Low accessibility due to high cost of hepatitis B treatment
One of the major problems from the treatment of hepatitis B is that not all the approved drugs are accessible to people and some are not affordable. Therefore, low accessibility due to the high cost of hepatitis B treatment is one the biggest challenges for the goal aiming to eliminate hepatitis B during our forecast period.
For the detailed list of factors that will drive and challenge the growth of the hepatitis B therapeutics market during the 2018-2022, view our report.
Competitive Landscape
The global hepatitis B therapeutics market is fairly fragmented and the market being in growth phase, the competition among companies is intense. Several companies are forming collaborations to increase their research toward the hepatitis B drug development. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY APPLICATION
• Segmentation by application
• Comparison by application
• Drugs – Market size and forecast 2017-2022
• Vaccines – Market size and forecast 2017-2022
• Market opportunity by application
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Strategic alliances
• Strong pipeline
• New technological advancements
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Gilead
• GlaxoSmithKline
• Merck Sharp & Dohme
PART 16: APPENDIX
• List of abbreviations


Exhibit 01: Parent market
Exhibit 02: Global infectious disease treatment market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global hepatitis B therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global hepatitis B therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 20
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Global hepatitis B therapeutics pipeline: Overview
Exhibit 20: Application – Market share 2017-2022 (%)
Exhibit 21: Comparison by application
Exhibit 22: Drugs – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Drugs – Year-over-year growth 2018-2022 (%)
Exhibit 24: Vaccines – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Vaccines – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by application
Exhibit 27: Customer landscape
Exhibit 28: Global – Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bristol-Myers Squibb – Overview
Exhibit 46: Bristol-Myers Squibb – Business segments
Exhibit 47: Bristol-Myers Squibb – Organizational developments
Exhibit 48: Bristol-Myers Squibb – Geographic focus
Exhibit 49: Bristol-Myers Squibb – Key offerings
Exhibit 50: Bristol-Myers Squibb – Key customers
Exhibit 51: F. Hoffmann-La Roche – Overview
Exhibit 52: F. Hoffmann-La Roche – Business segments
Exhibit 53: F. Hoffmann-La Roche – Organizational developments
Exhibit 54: F. Hoffmann-La Roche – Geographic focus
Exhibit 55: F. Hoffmann-La Roche – Segment focus
Exhibit 56: F. Hoffmann-La Roche – Key offerings
Exhibit 57: F. Hoffmann-La Roche – Key customers
Exhibit 58: Gilead – Overview
Exhibit 59: Gilead – Business segments
Exhibit 60: Gilead – Organizational developments
Exhibit 61: Gilead – Geographic focus
Exhibit 62: Gilead – Key offerings
Exhibit 63: Gilead – Key customers
Exhibit 64: GlaxoSmithKline – Overview
Exhibit 65: GlaxoSmithKline – Business segments
Exhibit 66: GlaxoSmithKline – Organizational developments
Exhibit 67: GlaxoSmithKline – Geographic focus
Exhibit 68: GlaxoSmithKline – Segment focus
Exhibit 69: GlaxoSmithKline – Key offerings
Exhibit 70: GlaxoSmithKline – Key customers
Exhibit 71: Merck Sharp & Dohme – Overview
Exhibit 72: Merck Sharp & Dohme – Business segments
Exhibit 73: Merck Sharp & Dohme – Organizational developments
Exhibit 74: Merck Sharp & Dohme – Geographic focus
Exhibit 75: Merck Sharp & Dohme – Segment focus
Exhibit 76: Merck Sharp & Dohme – Key offerings
Exhibit 77: Merck Sharp & Dohme – Key customers



【掲載企業】

Bristol-Myers Squibb、F. Hoffmann-La Roche、Gilead、GlaxoSmithKline、and Merck Sharp & Dohme

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[B型肝炎治療薬の世界市場2018-2022]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆